MacroPore regenerates
This article was originally published in The Gray Sheet
Executive Summary
MacroPore Biosurgery changes name to Cytori Therapeutics in effort to align corporate image with focus on stem cell regenerative therapeutics 1("The Gray Sheet" Aug. 23, 2004, p.14). Cytori's stem cell research concerns therapies for cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. The company will continue to make bioresorbable surgical implants distributed by Medtronic...